Fact CheckerSign in

NCT06510231Recruiting

Inspiratory Muscle Training in HFpEF

Inspiratory Muscle Training in Heart Failure With Preserved Ejection Fraction

Source: ClinicalTrials.gov · Last updated 7 Aug 2026

Brief summary (registry, in English)

This study is being done to determine how inspiratory muscle training impacts inspiratory muscle function during exercise in heart failure patients.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
68 (estimated)
First submitted
15 Jul 2024
Start date
9 Oct 2024
Primary completion date
Apr 2028
Lead sponsor
Mayo Clinic
NCT number
NCT06510231

What you commit to

  • Study type: Interventional
  • Planned participants: 68
  • From 9 Oct 2024 to the primary completion date, Apr 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Second or third degree heart block
  • Uremia, history of allergy to iodides
  • Peripheral artery disease
  • Ruptured eardrum or any other condition of the ear
  • History of spontaneous pneumothorax or osteoporosis with a history of rib fractures
  • History of lidocaine allergy.
    • For individuals agreeing to undergo dual energy x-ray absorptiometry (DEXA) scanning for measurement of body composition as part of their study visit, additional exclusion criteria apply: recently administered gastrointestinal contrast or radionuclides; severe degenerative changes or fracture deformity in measurement areas; or inability to attain correct position and/or remain motionless for the measurement period.

Lab values

  • Alanine transaminase and/or aspartate transaminase greater than 2 times the upper limit of normal (via clinical record within the past 6 months)

Other

  • Sustained ventricular tachycardia and/or ventricular fibrillation within 21 days of visit 1
  • Body mass index \>40 kg/m2
  • Current smokers and/or smoking history \>20 pack years
  • Pregnant women (testing will be done by research team if requested)
  • Glomerular filtration rate of \<30 mL/min/1.73m2 (initial screen via clinical record within the past 6 months and this will be assessed on Visit 1)
  • Individuals who are not able to engage in exercise
  • Asthmatic patients with a low symptom perception and suffer frequency, severe exacerbations or with an abnormally low perception of dyspnea

Who the study is looking for

  • ≥18 yrs of age
  • Receiving SGLT2 inhibitors and spironolactone (and beta-blocker use for HFpEF patients with hypertension) for \>3 months
  • NYHA symptoms I-III
  • Body mass index ≤40 kg/m2
  • Currently non-smokers with \<20 pack year history
  • Able to exercise (i.e. without significant orthopedic limitations or musculoskeletal disorders limiting their ability to exercise)

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Mayo Clinic in Rochester
Coordinator of this site? Confirm its status
RochesterUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.